1. Home
  2. NVAX vs CIM Comparison

NVAX vs CIM Comparison

Compare NVAX & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • CIM
  • Stock Information
  • Founded
  • NVAX 1987
  • CIM 2007
  • Country
  • NVAX United States
  • CIM United States
  • Employees
  • NVAX N/A
  • CIM N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • CIM Real Estate Investment Trusts
  • Sector
  • NVAX Health Care
  • CIM Real Estate
  • Exchange
  • NVAX Nasdaq
  • CIM Nasdaq
  • Market Cap
  • NVAX 1.3B
  • CIM 965.2M
  • IPO Year
  • NVAX 1995
  • CIM 2007
  • Fundamental
  • Price
  • NVAX $6.66
  • CIM $12.79
  • Analyst Decision
  • NVAX Buy
  • CIM Hold
  • Analyst Count
  • NVAX 6
  • CIM 2
  • Target Price
  • NVAX $17.83
  • CIM $16.00
  • AVG Volume (30 Days)
  • NVAX 8.5M
  • CIM 533.6K
  • Earning Date
  • NVAX 05-08-2025
  • CIM 05-08-2025
  • Dividend Yield
  • NVAX N/A
  • CIM 11.56%
  • EPS Growth
  • NVAX N/A
  • CIM N/A
  • EPS
  • NVAX 2.97
  • CIM 1.52
  • Revenue
  • NVAX $1,254,962,000.00
  • CIM $326,755,000.00
  • Revenue This Year
  • NVAX N/A
  • CIM $11.59
  • Revenue Next Year
  • NVAX N/A
  • CIM $2.13
  • P/E Ratio
  • NVAX $2.24
  • CIM $8.43
  • Revenue Growth
  • NVAX 25.92
  • CIM 11.90
  • 52 Week Low
  • NVAX $4.43
  • CIM $9.85
  • 52 Week High
  • NVAX $23.86
  • CIM $16.89
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.25
  • CIM 59.93
  • Support Level
  • NVAX $5.82
  • CIM $11.96
  • Resistance Level
  • NVAX $6.61
  • CIM $12.52
  • Average True Range (ATR)
  • NVAX 0.53
  • CIM 0.33
  • MACD
  • NVAX 0.02
  • CIM 0.16
  • Stochastic Oscillator
  • NVAX 42.21
  • CIM 78.95

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About CIM Chimera Investment Corporation

Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.

Share on Social Networks: